Who is sponsoring NCT03870113?

NCT03870113 is sponsored by Shenzhen People's Hospital.

What drugs are being tested in NCT03870113?

Interventions in NCT03870113: Vaccinated group.

What condition does NCT03870113 study?

NCT03870113 studies Cervical Intraepithelial Neoplasia.

Is NCT03870113 still recruiting?

NCT03870113 is currently status unknown. Last updated 14 March 2019.

Last reviewed 2019-03-14 · How we verify

NCT03870113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2

Status unknown Phase 1 Last updated 14 March 2019

What this trial tests

Phase 1 trial testing Vaccinated group in Cervical Intraepithelial Neoplasia in 80 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
31 March 2022

30 December 2022

Quick facts

Lead sponsor	Shenzhen People's Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 April 2019
Primary completion	31 March 2022
Estimated completion	30 December 2022
Sites	1 location across China

Drugs / interventions tested

Vaccinated group

Conditions studied

Cervical Intraepithelial Neoplasia — all drugs for Cervical Intraepithelial Neoplasia →

Sponsor

Shenzhen People's Hospital

Who can join

Adults 18 to 70, female only, with Cervical Intraepithelial Neoplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish therapeutic dendritic cell (DC) vaccines targeting HPV 16/18 E6/E7 protein to block the progression of CIN1/CIN2 to cervical cancer and evaluate the safety and efficacy of the vaccines.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives.
Mo Y, Ma J, Zhang H, Shen J, et al · · 2022 · cited 90× · PMID 35860379 · DOI 10.3389/fcimb.2022.909223
Therapeutic Vaccines for HPV-Associated Malignancies.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, et al · · 2020 · cited 87× · PMID 33117742 · DOI 10.2147/itt.s273327
Current and future direction in treatment of HPV-related cervical disease.
Khairkhah N, Bolhassani A, Najafipour R. · · 2022 · cited 44× · PMID 35478255 · DOI 10.1007/s00109-022-02199-y
A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.
Shin MB, Liu G, Mugo N, Garcia PJ, et al · · 2021 · cited 43× · PMID 34277540 · DOI 10.3389/fpubh.2021.670032
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
Therapeutic Vaccination for HPV-Mediated Cancers.
Yan F, Cowell LG, Tomkies A, Day AT. · · 2023 · cited 26× · PMID 36743978 · DOI 10.1007/s40136-023-00443-8

Verify or expand the search:

Other recruiting trials for Cervical Intraepithelial Neoplasia

Currently open trials in the same condition.

NCT07275333 — Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine · NA · recruiting
NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
NCT06810427 — A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings · NA · active not recruiting
NCT06191133 — Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma · Phase 1 · recruiting
NCT06243666 — Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls · active not recruiting

Other Shenzhen People's Hospital trials

Trials by the same sponsor.

NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03870113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
Last refreshed: 14 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03870113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing